Search
Publications
Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial
P. Sonneveld, A. Chanan-Khan, K. Weisel, A. K. Nooka, T. Masszi, M. Beksac, I. Spicka, V. Hungria, M. Munder, M.
Gdf -11 a new target to improve anemia in thalassemia.
β-thalassemias are characterized by ineffective red blood cell (RBC) production, leading to anemia, iron overload, and organ failure. As current treatment options for β-thalassemia are limited, there is a clear unmet need for alternative therapies.
Highlights of Past EHA (HOPE ) Asia 2021 - report
In the first weekend of September (September 3-4), EHA opened the virtual platform for HOPE Asia 2021.
Read moreEHA Kick-off Grant review and selection process
1. Eligibility checkAfter the deadline has passed, we'll check your application for completion and compliance with the eligibility criteria.
Read moreMeeting report | HOPE ASIA 2019 Kolkata
The first edition of the Highlights of Past EHA (HOPE) in Asia was held in Kolkata, India and was a great success.
Read more“Complement-ing” positive outcomes during the COVID-19 pandemic
Dr Dimitrios Mastellos (@dmastellos)
The COVID-19 pandemic has had a huge impact on research worldwide. Multiple projects have been halted and researchers have lost their jobs.